4.2 Article

Confounder summary scores when comparing the effects of multiple drug exposures

Journal

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
Volume 19, Issue 1, Pages 2-9

Publisher

WILEY
DOI: 10.1002/pds.1845

Keywords

drug evaluation; epidemiology; pharmaceutical; epidemiological methods; population studies

Funding

  1. University of Toronto Connaught Start-Up Award
  2. Canadian Institutes of Health Research (CIHR) Post-Doctoral Fellowship
  3. National Institute of Arthritis and Muskuloskeletal and Skin Diseases [K24 AR02123, P60 AR47782]
  4. Arthritis Foundation
  5. National Institutes of Health [P60 AR47782, K24 AR055989, R21 AG027066]
  6. National Institute on Aging [RO1 AG023178]
  7. UNC-GSK Center for Excellence in Pharmacoepidemiology and Public Health
  8. NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR047782, K24AR002123, K24AR055989] Funding Source: NIH RePORTER
  9. NATIONAL INSTITUTE ON AGING [R21AG027066, R01AG023178] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Purpose Little information is available comparing methods to adjust for confounding when considering multiple drug exposures. We compared three analytic strategies to control for confounding based on measured variables: conventional multivariable, exposure propensity score (EPS), and disease risk score (DRS). Methods Each method was applied to a dataset (2000-2006) recently used to examine the comparative effectiveness of four drugs. The relative effectiveness of risedronate, nasal calcitonin, and raloxifene in preventing non-vertebral fracture, were each compared to alendronate. EPSs were derived both by using multinomial logistic regression (single model EPS) and by three separate logistic regression models (separate model EPS). DRSs were derived and event rates compared using Cox proportional hazard models. DRSs derived among the entire cohort (full cohort DRS) was compared to DRSs derived only among the referent alendronate (unexposed cohort DRS). Results Less than 8% deviation from the base estimate (conventional multivariable) was observed applying single model EPS, separate model EPS or full cohort DRS. Applying the unexposed cohort DRS when background risk for fracture differed between comparison drug exposure cohorts resulted in -7 to + 13% deviation from our base estimate. Conclusions With sufficient numbers of exposed and outcomes, either conventional multivariable, EPS or full cohort DRS may be used to adjust for confounding to compare the effects of multiple drug exposures. However, our data also suggest that unexposed cohort DRS may be problematic when background risks differ between referent and exposed groups. Further empirical and simulation studies will help to clarify the generalizability of our findings. Copyright (c) 2009 John Wiley & Sons, Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Endocrinology & Metabolism

Effectiveness of Oral Bisphosphonates in Reducing Fracture Risk Among Oral Glucocorticoid Users: Three Matched Cohort Analyses

M. Amine Amiche, Linda E. Levesque, Tara Gomes, Jonathan D. Adachi, Suzanne M. Cadarette

JOURNAL OF BONE AND MINERAL RESEARCH (2018)

Article Pharmacology & Pharmacy

Increased risk of all-cause mortality associated with domperidone use in Parkinson's patients: a population-based cohort study in the UK

Marina Simeonova, Frank de Vries, Sander Pouwels, Johanna H. M. Driessen, Hubert G. M. Leufkens, Suzanne M. Cadarette, Andrea M. Burden

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)

Article Clinical Neurology

The lifetime cost of spinal cord injury in Ontario, Canada: A population-based study from the perspective of the public health care payer

Brian Chun-Fai Chan, Suzanne M. Cadarette, Walter P. Wodchis, Murray D. Krahn, Nicole Mittmann

JOURNAL OF SPINAL CORD MEDICINE (2019)

Article Medicine, General & Internal

History and publication trends in the diffusion and early uptake of indirect comparison meta-analytic methods to study drugs: animated coauthorship networks over time

Joann K. Ban, Mina Tadrous, Amy X. Lu, Erin A. Cicinelli, Suzanne M. Cadarette

BMJ OPEN (2018)

Article Endocrinology & Metabolism

Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study

M. Amine Amiche, Shahab Abtahi, Johanna H. M. Driessen, Peter Vestergaard, Frank de Vries, Suzanne M. Cadarette, Andrea M. Burden

ARCHIVES OF OSTEOPOROSIS (2018)

Article Endocrinology & Metabolism

Analysis of Trends in Insulin Utilization and Spending Across Canada From 2010 to 2015

Yina Xu, Tara Gomes, Muhammad M. Mamdani, David N. Juurlink, Suzanne M. Cadarette, Mina Tadrous

CANADIAN JOURNAL OF DIABETES (2019)

Article Substance Abuse

Impact of timing of methadone initiation on perinatal outcomes following delivery among pregnant women on methadone maintenance therapy in Ontario

Qi Guan, Beth A. Sproule, Simone N. Vigod, Suzanne M. Cadarette, Simon Greaves, Diana Martins, Tara Gomes

ADDICTION (2019)

Article Endocrinology & Metabolism

Five-year refracture rates of a province-wide fracture liaison service

R. Sujic, D. E. Beaton, M. Mamdani, S. M. Cadarette, J. Luo, S. Jaglal, J. E. M. Sale, R. Jain, E. Bogoch

OSTEOPOROSIS INTERNATIONAL (2019)

Article Endocrinology & Metabolism

Time trends in oral bisphosphonate initiation in Ontario, Canada over 20 years reflect drug policy and healthcare delivery changes

K. N. Hayes, J. K. Ban, G. Athanasiadis, A. M. Burden, S. M. Cadarette

OSTEOPOROSIS INTERNATIONAL (2019)

Article Endocrinology & Metabolism

Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap

J. K. Ban, B. B. Hao, L. McCarthy, S. J. T. Guilcher, S. M. Cadarette

OSTEOPOROSIS INTERNATIONAL (2019)

Article Endocrinology & Metabolism

Temporal Trends and Factors Associated with Bisphosphonate Discontinuation and Restart

Giovanni Adami, Ayesha Jaleel, Jeffrey R. Curtis, Elizabeth Delzell, Rui Chen, Huifeng Yun, Shanette Daigle, Tarun Arora, Maria I. Danila, Nicole C. Wright, Suzanne M. Cadarette, Amy Mudano, Jeffrey Foster, Kenneth G. Saag

JOURNAL OF BONE AND MINERAL RESEARCH (2020)

Article Multidisciplinary Sciences

External validation of clinical prediction rules for complications and mortality following Clostridioides difficile infection

Catherine Beauregard-Paultre, Claire Nour Abou Chakra, Allison McGeer, Annie-Claude Labbe, Andrew E. Simor, Wayne Gold, Matthew P. Muller, Jeff Powis, Kevin Katz, Suzanne M. Cadarette, Jacques Pepin, Louis Valiquette

PLOS ONE (2019)

Article Medicine, General & Internal

Design choices for observational studies of the effect of exposure on disease incidence

Mitchell H. Gail, Douglas G. Altman, Suzanne M. Cadarette, Gary Collins, Stephen J. W. Evans, Peggy Sekula, Elizabeth Williamson, Mark Woodward

BMJ OPEN (2019)

Review Medicine, General & Internal

Duration of Bisphosphonate Drug Holidays in Osteoporosis Patients: A Narrative Review of the Evidence and Considerations for Decision-Making

Kaleen N. Hayes, Elizabeth M. Winter, Suzanne M. Cadarette, Andrea M. Burden

Summary: Bisphosphonates are the primary treatment for osteoporosis, and a drug holiday of two to three years is recommended for most patients after long-term use to reduce the risk of adverse events. Duration of bisphosphonate effects during the drug holiday and individual patient factors should be considered when determining the appropriate time to stop therapy.

JOURNAL OF CLINICAL MEDICINE (2021)

Article Pharmacology & Pharmacy

Comparison of Fracture Identification Using Different Definitions in Healthcare Administrative (Claims) Data

Natalia Konstantelos, Andrea M. Burden, Angela M. Cheung, Sandra Kim, Paul Grootendorst, Suzanne M. Cadarette

Summary: This study aimed to compare fracture rates estimated using different definitions and found that coding decisions have a significant impact on fracture outcome definitions. The study highlights the importance and impact of coding decisions on fracture outcome identification and emphasizes the need for further research to inform best practice in fracture outcome identification.

PHARMACY (2023)

No Data Available